top of page
Cellbrain.jpg

TM

CellBrain     

CELL THERAPY TESTING

BIO​MATERIAL BIOCOMPATIBILITY TESTING

HUMAN BRAIN ORGANOID MODEL

ADVANTAGES OF CELLBRAIN
Glioblastoma invasion model

    Short-term and Long-term compound testing
    3-dimensional human tissues

    Highly physiological neural tissue interactions

    Monitoring of cell / polymer integration in the neural tissue

Point.jpg
Point.jpg
Point.jpg
Point.jpg

TM

CellBrain is an advanced testing service designed to evaluate the effectiveness and safety of cell therapy or biomaterial therapy in human brain tissue. The efficiency of cell therapy is assessed using fluorescent single-cell suspensions or spheroids (depicted in red) as shown in the scheme below. These cells are then seeded onto the neural tissue, and their spreading is easily monitored through fluorescence measurement. A similar experimental pipeline is followed for biomaterial therapy (depicted in blue), with the integration of the biomaterial in the neural tissue finally measured.

CellBrain1.jpg

The long term treatment testing, 3D human organoids and physiological cell/biomaterial - tissue interactions makes CellBrain advantageous compared to currently used 2D as well as animal models.
CellBrain represents an ideal tool for lead treatment screening and validation through efficiency testing, or deeper histological, proteomic and genomic testing for mechanistic studies.

MONITORING CELL SURVIVAL AND SPREADING
Following fluorescent cell injection in the neural tissue, their survival, integration, and spreading can be monitored.

CellBrain2.jpg

Fig. A: As an example, seven days after the injection of fluorescent cells into the neural tissue, we measure fluorescence. The white circle in the left panel represents the seeding zone, and all cells outside of this zone are considered motile and quantified in the middle panel. The right panels quantify total fluorescence to assess cell survival.

BIOMATERIAL BIOCOMPATIBILITY MEASUREMENT
We provide a multi-parameter approach to assess the biocompatibility of a biomaterial: the volume occupied by cells, its influence on cell viability, and on cell differentiation.

CellBrain3.jpg

Fig. B: In the left panel, histological analysis displays a high biomaterial penetration in the neural tissue: neurons in red (bIII-tubulin) and biomaterial in green. Multiparameter quantification reveals the volume occupied by cells and their viability. Genomic analysis shows biomaterial 2 promotes neuronal migration, while no cell-dependent effect is observed for biomaterials 1 and 3.

CELLBRAIN   CELL THERAPY & BIOMATERIAL BIOCOMPATIBILITY TESTING - SERVICE SPECIFICATION

Cell types

 

 

Production technology
 

Field of application
 

Assay window
Readouts

TM

 

3D Neural tissue: Minibrain generated from human pluripotent stem cells. Composed of neurons, astrocytes, oligodendrocytes and neural progenitor cells. The latter cells keep generating newborn neurons in a dynamic process.
Neurix’s MinibrainTM & Neurosphere technology with minimum batch to batch variability guaranteed by extensive quality control of identity (rt-qPCR)
- Lead compound validation

- High throughput screening (for cell therapy only)
Short term (7 days) to long term (one month)
- Cell viability

- Cell apoptosis

- Cell motility

- Biomaterial volume occupied by cells

- Cell-type dependent effects

OUR PUBLICATIONS
Nayernia, Z. et al. The relationship between brain tumor cell invasion of engineered neural tissues and in vivo features of glioblastoma. Biomaterials 34, 8279–8290 (2013)
Bonini F., Bratschler T. et. Al., in preparation

VALIDATED ASSAYS AND PROTOCOLS
The CellBrain service is integrated into a variety of validated assays that can be implemented in drug development for the efficacy evaluation of novel compounds:
    Cell viability assays
    Histological analysis (IHC & IF)                    
    Cell sorting and cell population analysis (FACS)

     Genomic analysis

     Proteomic analysis

Point.jpg
Point.jpg
Point.jpg
Point.jpg
Point.jpg

CONTACT US, CONTACT OUR TEAM

At Neurix, we provide tailored services for various neural applications, such as gene/cell/polymer therapy testing, brain tumor drug testing, modeling neurodegenerative diseases, and conducting neurotoxicity assays. Our team of experienced scientists is dedicated to collaborating with you to comprehend your requirements and achieve your goals.

Email: info@neurix.ch 

Phone: +41 22 379 46 43

 

Location: Avenue de la Roseraie 64

1205 Geneva, Switzerland

bottom of page